STAAR Surgical Insider Awarded New Equity Grants in 2025 Filing

Rhea-AI Filing Summary

Form 4 overview: On 06/18/2025 STAAR Surgical Co. (STAA) granted Director Arthur C. Butcher equity under its 2025-2026 non-employee director compensation program.

• Restricted Stock Units (RSUs): 5,341 units acquired at $0. Each RSU converts into one common share when vested. Vesting occurs in full on the earlier of 18 Jun 2026 or the company’s 2026 annual meeting.
• Stock options: 9,708 options with a $16.85 exercise price. Options vest 18 Jun 2026 and expire 17 Jun 2035.

No dispositions were reported; all transactions are coded “A” (acquisition). Ownership is listed as direct, indicating the director holds the awards personally. The filing is routine compensation disclosure and does not contain earnings or operational data.

Positive

• Alignment of interests: Director received equity (RSUs and options), increasing exposure to STAA share performance.
• No share sales: Filing shows only acquisitions; no indication of insider selling pressure.

Negative

• Potential dilution: 15,049 additional shares/options add minimally to share count, creating a small future overhang.

Insights

Corporate Governance Expert

TL;DR Routine director equity grant: 5,341 RSUs + 9,708 options at $16.85; neutral market impact.

The Form 4 documents standard annual equity compensation for a non-employee director. The mix of full-value RSUs and long-dated options is typical and aligns director incentives with shareholder value. No shares were sold, so there is no immediate selling pressure. Grant sizes are modest relative to typical mid-cap governance practices and provide a clear one-year cliff vesting schedule, reinforcing retention until the 2026 shareholder meeting. Because the awards are pre-planned and carry no new strategic information, the disclosure is informational rather than market-moving.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Butcher Arthur C

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	06/18/2025		A		5,341		(2)	(2)	Common Stock	5,341	$0	5,341	D
Common Stock Options	$16.85	06/18/2025		A		9,708		06/18/2026(2)	06/17/2035	Common Stock	9,708	$0	9,708	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.

2. These equity awards vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Remarks:

This Form 4 reflects the equity awards granted to the Reporting Person on June 18, 2025, pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Arthur Butcher	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did STAA Director Arthur Butcher acquire on 06/18/2025?

The director acquired 5,341 RSUs and 9,708 stock options, totaling 15,049 share-linked awards.

What is the exercise price of the new STAAR Surgical (STAA) stock options?

The options carry a $16.85 exercise price.

When do the RSUs and options granted to the STAA director vest?

Both the RSUs and the options vest fully on 18 Jun 2026 or at the 2026 annual meeting, whichever comes first.

Did the Form 4 report any insider sales of STAA shares?

No. The filing lists only acquisitions; there were no dispositions of common stock.

Is this insider transaction under a Rule 10b5-1 trading plan?

The form leaves the new 10b5-1 checkbox unchecked, indicating the grant is not tied to a 10b5-1 plan.